10-QPeriod: Q2 FY2001

QUEST DIAGNOSTICS INC Quarterly Report for Q2 Ended Jun 30, 2001

Filed August 9, 2001For Securities:DGX

Summary

Quest Diagnostics Incorporated reported financial results for the quarter and six months ended June 30, 2001. The company saw a notable increase in income before extraordinary loss, rising to $47.1 million for the quarter and $82.9 million for the six-month period, up from $30.2 million and $48.0 million respectively in the prior year. This growth was primarily driven by improvements in average revenue per requisition, successful realization of synergies from the SBCL integration, and a reduction in net interest expense. However, these positive trends were partially offset by an extraordinary loss of $21.6 million (net of tax) related to a significant debt refinancing completed in June 2001. Despite this one-time charge, the underlying operational performance shows strength, with adjusted EBITDA increasing by 16.0% year-over-year for the quarter and 15.0% for the six-month period, reflecting improved revenue per test and cost efficiencies.

Key Highlights

  • 1Net revenues increased by 8.0% for the quarter and 7.5% for the six months ended June 30, 2001, compared to the prior year, excluding the impact of third-party testing arrangements in 2000.
  • 2Income before extraordinary loss saw significant year-over-year growth, increasing by 61% for the quarter and 76% for the six months, indicating strong operational performance.
  • 3A major debt refinancing was completed in June 2001, involving a $550 million senior notes offering and a new $500 million credit facility, which is expected to lower annual interest expense.
  • 4The company recorded an extraordinary loss of $21.6 million (net of tax) related to the debt refinancing, primarily due to deferred financing costs and tender premiums on subordinated notes.
  • 5Synergies from the SBCL integration continue to be realized, with an estimated annual rate of $120 million achieved by the end of Q2 2001, contributing to cost efficiencies.
  • 6Capital expenditures for the six months were $78.4 million, and business acquisitions totaled $55.7 million, including the acquisition of Clinical Laboratories of Colorado (CLC).
  • 7Bad debt expense as a percentage of net revenues improved to 6.0% for the quarter and 6.1% for the six months, reflecting progress in billing and collection efficiency.

Frequently Asked Questions

Revenue growth was primarily driven by an improvement in average revenue per requisition, which increased by 7.9% for the quarter. This was attributed to better pricing on managed care business, a shift towards higher-value testing, and a favorable change in payer mix towards fee-for-service reimbursement.

In June 2001, Quest Diagnostics completed a significant debt refinancing. This involved issuing $550 million in senior notes and securing a new $500 million credit facility. While this is expected to reduce future interest expenses, it resulted in an extraordinary loss of $21.6 million (net of tax) during the second quarter, primarily from writing off deferred financing costs and tender premiums.

The integration of SBCL is substantially complete, with physical consolidations finalized by June 30, 2001. The company continues to realize significant synergies, with an estimated annual rate of $120 million achieved by the end of Q2 2001. These synergies are contributing to cost reductions and improved operational efficiency.

The company expects a reduction in amortization of intangible assets starting January 1, 2002, due to the adoption of new accounting standards SFAS 141 and SFAS 142. These standards will change the accounting for business combinations and goodwill, moving towards a non-amortization approach for goodwill and certain intangibles, which will be reviewed for impairment instead.